First Header Logo Second Header Logo

Connection

Peter Clark to Urinary Bladder Neoplasms

Back to Details
This is a "connection" page, showing publications Peter Clark has written about Urinary Bladder Neoplasms.
Peter Clark
Connection Strength
12.613
Urinary Bladder Neoplasms
  1. Clark PE, Spiess PE, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, Efstathiou JA, Flaig TW, Friedlander T, Greenberg RE, Guru KA, Hahn N, Herr HW, Hoimes C, Inman BA, Kader AK, Kibel AS, Kuzel TM, Lele SM, Meeks JJ, Michalski J, Montgomery JS, Pagliaro LC, Pal SK, Patterson A, Petrylak D, Plimack ER, Pohar KS, Porter MP, Sexton WJ, Siefker-Radtke AO, Sonpavde G, Tward J, Wile G, Dwyer MA, Smith C. NCCN Guidelines Insights: Bladder Cancer, Version 2.2016. J Natl Compr Canc Netw. 2016 10; 14(10):1213-1224.
    View in: PubMed
    Score: 0.482
  2. Scarpato KR, Tyson MD, Clark PE. Natural biology and management of nonmuscle invasive bladder cancer. Curr Opin Oncol. 2016 May; 28(3):210-5.
    View in: PubMed
    Score: 0.468
  3. Clark PE. Toward Personalized Guidelines in Bladder Cancer. J Natl Compr Canc Netw. 2015 Dec; 13(12):1458-60.
    View in: PubMed
    Score: 0.455
  4. Clark PE. Urothelial carcinoma with squamous differentiation: response to chemotherapy and radiation. Urol Oncol. 2015 Oct; 33(10):434-6.
    View in: PubMed
    Score: 0.445
  5. Eifler JB, Scarpato KR, Clark PE. Management of noninvasive bladder cancers. Curr Opin Oncol. 2015 May; 27(3):185-90.
    View in: PubMed
    Score: 0.437
  6. Bassett JC, Eifler JB, Resnick MJ, Clark PE. Developments and controversies in the management of noninvasive bladder cancer. Curr Opin Oncol. 2014 May; 26(3):299-304.
    View in: PubMed
    Score: 0.407
  7. Clark PE. T1 high-grade bladder cancer recurring after BCG therapy: radical cystectomy is still the best approach. Pro. Oncology (Williston Park). 2013 Sep; 27(9):872, 921.
    View in: PubMed
    Score: 0.389
  8. Resnick MJ, Bassett JC, Clark PE. Management of superficial and muscle-invasive urothelial cancers of the bladder. Curr Opin Oncol. 2013 May; 25(3):281-8.
    View in: PubMed
    Score: 0.380
  9. Clark PE, Agarwal N, Biagioli MC, Eisenberger MA, Greenberg RE, Herr HW, Inman BA, Kuban DA, Kuzel TM, Lele SM, Michalski J, Pagliaro LC, Pal SK, Patterson A, Plimack ER, Pohar KS, Porter MP, Richie JP, Sexton WJ, Shipley WU, Small EJ, Spiess PE, Trump DL, Wile G, Wilson TG, Dwyer M, Ho M. Bladder cancer. J Natl Compr Canc Netw. 2013 Apr 01; 11(4):446-75.
    View in: PubMed
    Score: 0.378
  10. Keegan KA, Resnick MJ, Clark PE. Multimodal therapies for muscle-invasive urothelial carcinoma of the bladder. Curr Opin Oncol. 2012 May; 24(3):278-83.
    View in: PubMed
    Score: 0.355
  11. Morgan TM, Keegan KA, Clark PE. Bladder cancer. Curr Opin Oncol. 2011 May; 23(3):275-82.
    View in: PubMed
    Score: 0.331
  12. DeGraff DJ, Clark PE. Detection of tumor cells in the bone offers independent prognostic value in bladder cancer patients: the clinical and basic science perspective. Eur Urol. 2011 Aug; 60(2):239-40.
    View in: PubMed
    Score: 0.323
  13. Morgan TM, Clark PE. Bladder cancer. Curr Opin Oncol. 2010 May; 22(3):242-9.
    View in: PubMed
    Score: 0.309
  14. Clark PE. Neoadjuvant versus adjuvant chemotherapy for muscle-invasive bladder cancer. Expert Rev Anticancer Ther. 2009 Jun; 9(6):821-30.
    View in: PubMed
    Score: 0.290
  15. Bischoff CJ, Clark PE. Bladder cancer. Curr Opin Oncol. 2009 May; 21(3):272-7.
    View in: PubMed
    Score: 0.288
  16. Boudreaux KJ, Chang SS, Lowrance WT, Rumohr JA, Barocas DA, Cookson MS, Smith JA, Clark PE. Comparison of American Joint Committee on Cancer pathologic stage T3a versus T3b urothelial carcinoma: analysis of patient outcomes. Cancer. 2009 Feb 15; 115(4):770-5.
    View in: PubMed
    Score: 0.284
  17. Barocas DA, Clark PE. Bladder cancer. Curr Opin Oncol. 2008 May; 20(3):307-14.
    View in: PubMed
    Score: 0.269
  18. Clark PE. Upper tract transitional cell carcinoma: finding a way forward. Cancer. 2007 Oct 15; 110(8):1648-9.
    View in: PubMed
    Score: 0.259
  19. Clark PE. Bladder cancer. Curr Opin Oncol. 2007 May; 19(3):241-7.
    View in: PubMed
    Score: 0.251
  20. Gwynn ES, Clark PE. Bladder cancer. Curr Opin Oncol. 2006 May; 18(3):277-83.
    View in: PubMed
    Score: 0.234
  21. Clark PE, Stein JP, Groshen SG, Cai J, Miranda G, Lieskovsky G, Skinner DG. Radical cystectomy in the elderly: comparison of clincal outcomes between younger and older patients. Cancer. 2005 Jul 01; 104(1):36-43.
    View in: PubMed
    Score: 0.221
  22. Clark PE, Hall MC. Contemporary management of the urethra in patients after radical cystectomy for bladder cancer. Urol Clin North Am. 2005 May; 32(2):199-206.
    View in: PubMed
    Score: 0.218
  23. Clark PE, Stein JP, Groshen SG, Cai J, Miranda G, Lieskovsky G, Skinner DG. Radical cystectomy in the elderly: Comparison of survival between younger and older patients. Cancer. 2005 Feb 01; 103(3):546-52.
    View in: PubMed
    Score: 0.215
  24. Clark PE, Stein JP, Groshen SG, Miranda G, Cai J, Lieskovsky G, Skinner DG. The management of urethral transitional cell carcinoma after radical cystectomy for invasive bladder cancer. J Urol. 2004 Oct; 172(4 Pt 1):1342-7.
    View in: PubMed
    Score: 0.210
  25. Clark PE. Urinary diversion after radical cystectomy. Curr Treat Options Oncol. 2002 Oct; 3(5):389-402.
    View in: PubMed
    Score: 0.183
  26. Grigg CM, Livasy C, He J, Hartman A, Clark PE, Zhu J, Raghavan D, Burgess EF. Human epidermal growth factor receptor 2 overexpression is frequently discordant between primary and metastatic urothelial carcinoma and is associated with intratumoral human epidermal growth factor receptor 2 heterogeneity. Hum Pathol. 2021 01; 107:96-103.
    View in: PubMed
    Score: 0.160
  27. Townsend WB, Worrilow WM, Robinson MM, Beano H, Parker B, Gaston KE, Clark PE, Riggs SB. Implementation of a Dedicated Enhanced Recovery after Surgery (ERAS) Program for Radical Cystectomy Patients is Associated With Decreased Postoperative Inpatient Opioid Usage and Pain Scores. Urology. 2020 09; 143:186-193.
    View in: PubMed
    Score: 0.155
  28. Beano H, He J, Hensel C, Worrilow W, Townsend W, Gaston K, Clark PE, Riggs S. Safety of decreasing ureteral stent duration following radical cystectomy. World J Urol. 2021 Feb; 39(2):473-479.
    View in: PubMed
    Score: 0.154
  29. Burgess EF, Livasy C, Trufan S, Hartman A, Guerreri R, Naso C, Clark PE, Grigg C, Symanowski J, Raghavan D. High aurora kinase expression identifies patients with muscle-invasive bladder cancer who have poor survival after neoadjuvant chemotherapy. Urol Oncol. 2019 12; 37(12):900-906.
    View in: PubMed
    Score: 0.148
  30. Clark PE, Klein EA. Surgery for invasive bladder tumors: technique and outcome. Curr Opin Urol. 1999 Sep; 9(5):413-8.
    View in: PubMed
    Score: 0.147
  31. Burgess EF, Livasy C, Hartman A, Robinson MM, Symanowski J, Naso C, Doherty S, Guerrieri R, Riggs S, Grigg CM, Clark PE, Raghavan D. Discordance of high PD-L1 expression in primary and metastatic urothelial carcinoma lesions. Urol Oncol. 2019 05; 37(5):299.e19-299.e25.
    View in: PubMed
    Score: 0.141
  32. Fernández MI, Brausi M, Clark PE, Cookson MS, Grossman HB, Khochikar M, Kiemeney LA, Malavaud B, Sanchez-Salas R, Soloway MS, Svatek RS, Vikram R, Vrieling A, Kamat AM. Epidemiology, prevention, screening, diagnosis, and evaluation: update of the ICUD-SIU joint consultation on bladder cancer. World J Urol. 2019 Jan; 37(1):3-13.
    View in: PubMed
    Score: 0.137
  33. Spiess PE, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, Clark PE, Downs TM, Efstathiou JA, Flaig TW, Friedlander T, Greenberg RE, Guru KA, Hahn N, Herr HW, Hoimes C, Inman BA, Jimbo M, Kader AK, Lele SM, Meeks JJ, Michalski J, Montgomery JS, Pagliaro LC, Pal SK, Patterson A, Plimack ER, Pohar KS, Porter MP, Preston MA, Sexton WJ, Siefker-Radtke AO, Sonpavde G, Tward J, Wile G, Dwyer MA, Gurski LA. Bladder Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2017 10; 15(10):1240-1267.
    View in: PubMed
    Score: 0.129
  34. Arnold Egloff SA, Du L, Loomans HA, Starchenko A, Su PF, Ketova T, Knoll PB, Wang J, Haddad AQ, Fadare O, Cates JM, Lotan Y, Shyr Y, Clark PE, Zijlstra A. Shed urinary ALCAM is an independent prognostic biomarker of three-year overall survival after cystectomy in patients with bladder cancer. Oncotarget. 2017 Jan 03; 8(1):722-741.
    View in: PubMed
    Score: 0.123
  35. Yamashita H, Amponsa VO, Warrick JI, Zheng Z, Clark PE, Raman JD, Wu XR, Mendelsohn C, DeGraff DJ. On a FOX hunt: functions of FOX transcriptional regulators in bladder cancer. Nat Rev Urol. 2017 Feb; 14(2):98-106.
    View in: PubMed
    Score: 0.122
  36. Pal SK, Agarwal N, Boorjian SA, Hahn NM, Siefker-Radtke AO, Clark PE, Plimack ER. National Comprehensive Cancer Network Recommendations on Molecular Profiling of Advanced Bladder Cancer. J Clin Oncol. 2016 09 20; 34(27):3346-8.
    View in: PubMed
    Score: 0.119
  37. Chang SS, Boorjian SA, Chou R, Clark PE, Daneshmand S, Konety BR, Pruthi R, Quale DZ, Ritch CR, Seigne JD, Skinner EC, Smith ND, McKiernan JM. Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Guideline. J Urol. 2016 Oct; 196(4):1021-9.
    View in: PubMed
    Score: 0.118
  38. Gregg JR, Emeruwa C, Wong J, Barocas DA, Chang SS, Clark PE, Cookson MS, Penson DF, Resnick MJ, Scarpato KR, Smith JA, Moses KA. Oncologic Outcomes after Anterior Exenteration for Muscle Invasive Bladder Cancer in Women. J Urol. 2016 Oct; 196(4):1030-5.
    View in: PubMed
    Score: 0.117
  39. Gregg JR, McCormick B, Wang L, Cohen P, Sun D, Penson DF, Smith JA, Clark PE, Cookson MS, Barocas DA, Resnick MJ, Moses KA, Chang SS. Short term complications from transurethral resection of bladder tumor. Can J Urol. 2016 Apr; 23(2):8198-203.
    View in: PubMed
    Score: 0.116
  40. Arnold SA, Loomans HA, Ketova T, Andl CD, Clark PE, Zijlstra A. Urinary oncofetal ED-A fibronectin correlates with poor prognosis in patients with bladder cancer. Clin Exp Metastasis. 2016 Jan; 33(1):29-44.
    View in: PubMed
    Score: 0.113
  41. Reddy OL, Cates JM, Gellert LL, Crist HS, Yang Z, Yamashita H, Taylor JA, Smith JA, Chang SS, Cookson MS, You C, Barocas DA, Grabowska MM, Ye F, Wu XR, Yi Y, Matusik RJ, Kaestner KH, Clark PE, DeGraff DJ. Loss of FOXA1 Drives Sexually Dimorphic Changes in Urothelial Differentiation and Is an Independent Predictor of Poor Prognosis in Bladder Cancer. Am J Pathol. 2015 May; 185(5):1385-95.
    View in: PubMed
    Score: 0.109
  42. Lin-Tsai O, Taylor JA, Clark PE, Adam RM, Wu XR, DeGraff DJ. Progress made in the use of animal models for the study of high-risk, nonmuscle invasive bladder cancer. Curr Opin Urol. 2014 Sep; 24(5):512-6.
    View in: PubMed
    Score: 0.104
  43. Ritch CR, Cookson MS, Chang SS, Clark PE, Resnick MJ, Penson DF, Smith JA, May AT, Anderson CB, You C, Lee H, Barocas DA. Impact of complications and hospital-free days on health related quality of life 1 year after radical cystectomy. J Urol. 2014 Nov; 192(5):1360-4.
    View in: PubMed
    Score: 0.103
  44. Ark JT, Keegan KA, Barocas DA, Morgan TM, Resnick MJ, You C, Cookson MS, Penson DF, Davis R, Clark PE, Smith JA, Chang SS. Incidence and predictors of understaging in patients with clinical T1 urothelial carcinoma undergoing radical cystectomy. BJU Int. 2014 Jun; 113(6):894-9.
    View in: PubMed
    Score: 0.101
  45. Thompson IM, Kappa SF, Morgan TM, Barocas DA, Bischoff CJ, Keegan KA, Stratton KL, Clark PE, Resnick MJ, Smith JA, Cookson MS, Chang SS. Blood loss associated with radical cystectomy: a prospective, randomized study comparing Impact LigaSure vs. stapling device. Urol Oncol. 2014 Jan; 32(1):45.e11-5.
    View in: PubMed
    Score: 0.098
  46. Ritch CR, Clark PE, Morgan TM. Restaging transurethral resection for non-muscle invasive bladder cancer: who, why, when, and how? Urol Clin North Am. 2013 May; 40(2):295-304.
    View in: PubMed
    Score: 0.094
  47. Davies JD, Simons CM, Ruhotina N, Barocas DA, Clark PE, Morgan TM. Anatomic basis for lymph node counts as measure of lymph node dissection extent: a cadaveric study. Urology. 2013 Feb; 81(2):358-63.
    View in: PubMed
    Score: 0.093
  48. Morgan TM, Barocas DA, Keegan KA, Cookson MS, Chang SS, Ni S, Clark PE, Smith JA, Penson DF. Volume outcomes of cystectomy--is it the surgeon or the setting? J Urol. 2012 Dec; 188(6):2139-44.
    View in: PubMed
    Score: 0.092
  49. Kamat AM, Hegarty PK, Gee JR, Clark PE, Svatek RS, Hegarty N, Shariat SF, Xylinas E, Schmitz-Dräger BJ, Lotan Y, Jenkins LC, Droller M, van Rhijn BW, Karakiewicz PI. ICUD-EAU International Consultation on Bladder Cancer 2012: Screening, diagnosis, and molecular markers. Eur Urol. 2013 Jan; 63(1):4-15.
    View in: PubMed
    Score: 0.091
  50. Morgan TM, Barocas DA, Penson DF, Chang SS, Ni S, Clark PE, Smith JA, Cookson MS. Lymph node yield at radical cystectomy predicts mortality in node-negative and not node-positive patients. Urology. 2012 Sep; 80(3):632-40.
    View in: PubMed
    Score: 0.090
  51. Anderson CB, Cookson MS, Chang SS, Clark PE, Smith JA, Kaufman MR. Voiding function in women with orthotopic neobladder urinary diversion. J Urol. 2012 Jul; 188(1):200-4.
    View in: PubMed
    Score: 0.089
  52. DeGraff DJ, Clark PE, Cates JM, Yamashita H, Robinson VL, Yu X, Smolkin ME, Chang SS, Cookson MS, Herrick MK, Shariat SF, Steinberg GD, Frierson HF, Wu XR, Theodorescu D, Matusik RJ. Loss of the urothelial differentiation marker FOXA1 is associated with high grade, late stage bladder cancer and increased tumor proliferation. PLoS One. 2012; 7(5):e36669.
    View in: PubMed
    Score: 0.089
  53. Lotan Y, Amiel G, Boorjian SA, Clark PE, Droller M, Gingrich JR, Guzzo TJ, Inman BA, Kamat AM, Karsh L, Nielsen ME, Smith ND, Shariat SF, Svatek RS, Taylor JM. Comprehensive handbook for developing a bladder cancer cystectomy database. Urol Oncol. 2013 Aug; 31(6):812-26.
    View in: PubMed
    Score: 0.086
  54. DeGraff DJ, Cates JM, Mauney JR, Clark PE, Matusik RJ, Adam RM. When urothelial differentiation pathways go wrong: implications for bladder cancer development and progression. Urol Oncol. 2013 Aug; 31(6):802-11.
    View in: PubMed
    Score: 0.085
  55. Morgan TM, Barocas DA, Chang SS, Phillips SE, Salem S, Clark PE, Penson DF, Smith JA, Cookson MS. The relationship between perioperative blood transfusion and overall mortality in patients undergoing radical cystectomy for bladder cancer. Urol Oncol. 2013 Aug; 31(6):871-7.
    View in: PubMed
    Score: 0.085
  56. Morgan TM, Keegan KA, Barocas DA, Ruhotina N, Phillips SE, Chang SS, Penson DF, Clark PE, Smith JA, Cookson MS. Predicting the probability of 90-day survival of elderly patients with bladder cancer treated with radical cystectomy. J Urol. 2011 Sep; 186(3):829-34.
    View in: PubMed
    Score: 0.084
  57. Aghazadeh MA, Barocas DA, Salem S, Clark PE, Cookson MS, Davis R, Gregg J, Stimson CJ, Smith JA, Chang SS. Determining factors for hospital discharge status after radical cystectomy in a large contemporary cohort. J Urol. 2011 Jan; 185(1):85-9.
    View in: PubMed
    Score: 0.080
  58. Gregg JR, Cookson MS, Phillips S, Salem S, Chang SS, Clark PE, Davis R, Stimson CJ, Aghazadeh M, Smith JA, Barocas DA. Effect of preoperative nutritional deficiency on mortality after radical cystectomy for bladder cancer. J Urol. 2011 Jan; 185(1):90-6.
    View in: PubMed
    Score: 0.080
  59. Stimson CJ, Chang SS, Barocas DA, Humphrey JE, Patel SG, Clark PE, Smith JA, Cookson MS. Early and late perioperative outcomes following radical cystectomy: 90-day readmissions, morbidity and mortality in a contemporary series. J Urol. 2010 Oct; 184(4):1296-300.
    View in: PubMed
    Score: 0.079
  60. Stimson CJ, Cookson MS, Barocas DA, Clark PE, Humphrey JE, Patel SG, Smith JA, Chang SS. Preoperative hydronephrosis predicts extravesical and node positive disease in patients undergoing cystectomy for bladder cancer. J Urol. 2010 May; 183(5):1732-7.
    View in: PubMed
    Score: 0.077
  61. Lowrance WT, Rumohr JA, Clark PE, Chang SS, Smith JA, Cookson MS. Urinary diversion trends at a high volume, single American tertiary care center. J Urol. 2009 Nov; 182(5):2369-74.
    View in: PubMed
    Score: 0.074
  62. Barocas DA, Patel SG, Chang SS, Clark PE, Smith JA, Cookson MS. Outcomes of patients undergoing radical cystoprostatectomy for bladder cancer with prostatic involvement on final pathology. BJU Int. 2009 Oct; 104(8):1091-7.
    View in: PubMed
    Score: 0.072
  63. Patel SG, Cookson MS, Barocas DA, Clark PE, Smith JA, Chang SS. Risk factors for urothelial carcinoma of the prostate in patients undergoing radical cystoprostatectomy for bladder cancer. BJU Int. 2009 Oct; 104(7):934-7.
    View in: PubMed
    Score: 0.071
  64. Montie JE, Clark PE, Eisenberger MA, El-Galley R, Greenberg RE, Herr HW, Hudes GR, Kuban DA, Kuzel TM, Lange PH, Lele SM, Michalski J, Patterson A, Pohar KS, Richie JP, Sexton WJ, Shipley WU, Small EJ, Trump DL, Walther PJ, Wilson TG. Bladder cancer. J Natl Compr Canc Netw. 2009 Jan; 7(1):8-39.
    View in: PubMed
    Score: 0.070
  65. Boudreaux KJ, Clark PE, Lowrance WT, Rumohr JA, Barocas DA, Cookson MS, Smith JA, Chang SS. Comparison of american joint committee on cancer pathological stage T2a versus T2b urothelial carcinoma: analysis of patient outcomes in organ confined bladder cancer. J Urol. 2009 Feb; 181(2):540-5; discussion 546.
    View in: PubMed
    Score: 0.070
  66. Barbieri CE, Lee B, Cookson MS, Bingham J, Clark PE, Smith JA, Chang SS. Association of procedure volume with radical cystectomy outcomes in a nationwide database. J Urol. 2007 Oct; 178(4 Pt 1):1418-21; discussion 1421-2.
    View in: PubMed
    Score: 0.064
  67. Gwynn ES, Clark PE, Hall MC. Recent advances in the treatment of bladder cancer. Expert Rev Anticancer Ther. 2005 Dec; 5(6):1023-30.
    View in: PubMed
    Score: 0.057
  68. Borden LS, Clark PE, Hall MC. Bladder cancer. Curr Opin Oncol. 2005 May; 17(3):275-80.
    View in: PubMed
    Score: 0.055
  69. Borden LS, Clark PE, Hall MC. Bladder cancer. Curr Opin Oncol. 2004 May; 16(3):257-62.
    View in: PubMed
    Score: 0.051
  70. Quek ML, Stein JP, Clark PE, Daneshmand S, Miranda G, Cai J, Groshen S, Cote RJ, Lieskovsky G, Quinn DI, Skinner DG. Microscopic and gross extravesical extension in pathological staging of bladder cancer. J Urol. 2004 Feb; 171(2 Pt 1):640-5.
    View in: PubMed
    Score: 0.050
  71. Quek ML, Stein JP, Clark PE, Daneshmand S, Miranda G, Cai J, Groshen S, Lieskovsky G, Quinn DI, Raghavan D, Skinner DG. Natural history of surgically treated bladder carcinoma with extravesical tumor extension. Cancer. 2003 Sep 01; 98(5):955-61.
    View in: PubMed
    Score: 0.049
  72. Borden LS, Clark PE, Hall MC. Bladder cancer. Curr Opin Oncol. 2003 May; 15(3):227-33.
    View in: PubMed
    Score: 0.048
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.